Table 1 Clinical and demographic characteristics of PTMC patients
Variable | Number (%) or mean (SD) |
|---|---|
Age (years) | 39.6 (14.8) |
Gender | |
Male | 31 (44.3%) |
Female | 39 (55.7%) |
BMI | 22.3 (3.6) |
Symptom duration (months) | 21.1 (38.7) |
Osserman’s classification | |
I | 5 (7.1%) |
IIa | 28 (40.0%) |
IIb | 30 (42.9%) |
III | 5 (7.1%) |
IV | 2 (2.9%) |
MGFA classification | |
I | 5 (7.1%) |
IIa | 13 (18.6%) |
IIb | 16 (22.9%) |
IIIa | 9 (12.9%) |
IIIb | 21 (30.0%) |
IVa | 1 (1.4%) |
IVb | 2 (2.9%) |
V | 3 (4.3%) |
QMG score | 14.1 (5.7) |
Preoperative medical therapy | 69 (98.6%) |
Prednisolone | 25 (21.4%), 8.2 (19.4) |
Plasma exchange | 4 (5.7%) |
Steroid pulse | 9 (12.9%) |
Immunoglobulin | 4 (5.7%) |
Pyridostigmine bromide | 69 (98.6%) |
No preoperative medical therapy | 1 (1.4%) |
Autoimmune diseases | |
Hyperthyroidism | 5 (7.1%) |
Hypothyroidism | 3 (4.3%) |
Gout | 1 (1.4%) |
Rheumatoid arthritis | 1 (1.4%) |
Systemic lupus erythematosus | 1 (1.4%) |
Without autoimmune diseases | 59 (84.3%) |
Operation approach | |
VATS | 53 (75.7%) |
Transsternal | 17 (24.3%) |
Clavien-Dindo classificationa | |
0 | 18 (25.7%) |
I | 1 (1.4%) |
II | 41 (58.6%) |
IIIa | 4 (5.7%) |
IIIb | 2 (2.9%) |
IVa | 4 (5.7%) |
Mechanical ventilation duration (h) | 203.0 (436.3) |
Duration of hospital stay (days) | 30.3 (28.3) |